CD14 and acute myeloid leukemia: Since Venetoclax is targeting the anti-apoptotic BCL-2 protein, we next checked BCL-2 mRNA expression levels in AML and overlaid the CD14+ Monocyte percentages for these cases (Fig. 3d).